Thomas W. Burnell - 20 Aug 2026 Form 4 Insider Report for INTERPACE BIOSCIENCES, INC. (IDXG)

Reporting relationship: CEO, President & Chairman, Director
Issuer ticker: IDXG
Reported as of: 20 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Aug 2026, 17:59:00 UTC
Prior SEC filing: 25 May 2021
Source filing: View source filing
Reporting owner signature: /s/ Thomas W. Burnell

Key filing fact

Thomas W. Burnell filed Form 4 for INTERPACE BIOSCIENCES, INC. (IDXG) on 20 Aug 2026.

Key facts

This page summarizes Thomas W. Burnell's Form 4 filing for INTERPACE BIOSCIENCES, INC. (IDXG).
5 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 20 Aug 2026, 17:59.

Change

Previous filing in this sequence was filed on 25 May 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001720219 Primary reporting owner

Burnell Thomas W.

Relationship: CEO, President & Chairman, Director
Address: C/O INTERPACE BIOSCIENCES, INC., 2001 ROUTE 46 WATERVIEW PLAZA, SUITE 310, PARSIPPANY
Signature: /s/ Thomas W. Burnell
Signature date: 20 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IDXG transaction

Common Stock

Options Exercise

Transaction value
Shares: +1,966,763
Change %: +2775%
Price: $0.000000^*
Shares after: 2,037,645
Date: 20 Aug 2026
Ownership: Direct
Footnotes: F1

IDXG transaction

Common Stock

Tax liability

Transaction value
Shares: -581,718
Change %: -29%
Price: $1.61^*
Shares after: 1,455,927
Date: 20 Aug 2026
Ownership: Direct
Footnotes: F2

IDXG holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 10,885
Date: 20 Aug 2026
Ownership: By spouse

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IDXG transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +1,966,763
Change %
Price: $0.000000^*
Shares after: 1,966,763
Date: 20 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,966,763
Exercise price
Footnotes: F3, F4

IDXG transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -1,966,763
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 20 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,966,763
Exercise price
Footnotes: F3, F4

IDXG transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +554,018
Change %
Price: $0.000000^*
Shares after: 554,018
Date: 20 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 554,018
Exercise price: $2.02
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Represents the conversion upon vesting of restricted stock units ("RSUs") into shares of common stock of Interpace Biosciences, Inc. (the "Issuer"). On August20, 2026, the Reporting Person was granted 1,966,763 RSUs, all of which vested upon grant and which amount includes an amount intended to satisfy the Reporting Person's tax obligations arising from the award.

Footnote F2

Represents shares returned to the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person received the net number of shares after the shares were returned to the Issuer to satisfy applicable tax withholding obligations.

Footnote F3

Each RSU represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc.

Footnote F4

On August 20, 2026, the Reporting Person was granted 1,966,763 RSUs, all of which vested upon grant and which amount includes an amount intended to satisfy the Reporting Person's tax obligations arising from the award.

Footnote F5

The options will vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date.